Person looking into a microscope

Department of Brain Health News

The UNLV Department of Brain Health will advance research, education, and practice to benefit brain health and the care and treatment of people with brain disorders across the life span. Our faculty specialize in several areas that range from basic and clinical research in neurodegenerative disease, neuropsychology, and occupational therapy.

Current Brain Health News

man in front of El Camino car
People | September 9, 2020

Coming to UNLV at a most unusual time, President Keith E. Whitfield remains undaunted and ready to make his mark as a Rebel.

A portrait of UNLV's new president Keith Whitfield on campus.
Campus News | August 10, 2020

As summer heats up, so do the accomplishments on UNLV’s campus.

A scientist in a white lab coat rests his hand on his chin
Research | July 16, 2020

Dr. Jeffrey Cummings examines drug pipeline for treatments, and finds reason for optimism.

A UNLV banner on campus.
Campus News | July 2, 2020

A collection of news stories featuring the people and programs of UNLV.

artist rendering of brain
Campus News | June 15, 2020

The Chambers-Grundy Center for Transformative Neuroscience will advance research and the science of treatment for Alzheimer’s and other neurological disorders.

Closeup woman holding her wrist in pain from using computer.
Business and Community | April 28, 2020

As remote work and distance learning become a way of life, UNLV occupational therapist Donna Costa offers hacks for a healthy home office and exercise routine.

Brain Health In The News

Alzheimer's & Dementia Weekly
October 12, 2020

To further incentivize innovative ideas and opportunities in Alzheimer's disease and related dementias research, the National Institute on Aging (NIA), part of the National Institutes of Health, in late summer 2020 funded four exploratory Alzheimer’s Disease Research Centers (ADRCs). These new centers will broaden current ADRC research initiatives with underrepresented populations such as African Americans, Native Americans, and those in rural communities, all of which have different risk factors for developing Alzheimer's and related dementias.

Yahoo!
October 6, 2020

EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the Phase 2 AscenD-LB study in patients with mild-to-moderate dementia with Lewy bodies (DLB) met its primary endpoint of demonstrating an improvement in cognition as assessed by the Neuropsychological Test Battery (NTB). In the double-blind placebo-controlled study, patients receiving neflamapimod three times daily (TID) demonstrated significant improvement on the NTB compared to those who received either placebo or neflamapimod twice daily (BID); p=0.015, effect size (Cohen's d)=0.52. In addition, statistically significant improvements (p<0.05) or trends (p<0.1) were evident on multiple secondary clinical endpoints. The full results have been accepted as a late-breaking abstract and will be shared on November 7, 2020 during an oral presentation at the 13th Clinical Trials in Alzheimer's Disease (CTAD) meeting.

PR Newswire
October 6, 2020

EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the Phase 2 AscenD-LB study in patients with mild-to-moderate dementia with Lewy bodies (DLB) met its primary endpoint of demonstrating an improvement in cognition as assessed by the Neuropsychological Test Battery (NTB). In the double-blind placebo-controlled study, patients receiving neflamapimod three times daily (TID) demonstrated significant improvement on the NTB compared to those who received either placebo or neflamapimod twice daily (BID); p=0.015, effect size (Cohen's d)=0.52. In addition, statistically significant improvements (p<0.05) or trends (p<0.1) were evident on multiple secondary clinical endpoints. The full results have been accepted as a late-breaking abstract and will be shared on November 7, 2020 during an oral presentation at the 13th Clinical Trials in Alzheimer's Disease (CTAD) meeting.

NASDAQ
September 15, 2020

Today's Daily Dose brings you news about Gilead's acquisition of Immunomedics, Marinus' CDKL5 deficiency disorder trial results, Seattle Genetics' oncology collaborations with Merck, 89bio's NASH trial data, and Cassava Sciences' Alzheimer's trial results.

Business Insider
September 15, 2020

Today's Daily Dose brings you news about Gilead's acquisition of Immunomedics, Marinus' CDKL5 deficiency disorder trial results, Seattle Genetics' oncology collaborations with Merck, 89bio's NASH trial data, and Cassava Sciences' Alzheimer's trial results.

EurekAlert!
September 10, 2020

To further incentivize innovative ideas and opportunities in Alzheimer's disease and related dementias research, the National Institute on Aging (NIA), part of the National Institutes of Health, has funded four exploratory Alzheimer's Disease Research Centers (ADRCs). These new centers will broaden current ADRC research initiatives with underrepresented populations such as African Americans, Native Americans, and those in rural communities -- all of which have different risk factors for developing these devastating diseases.

Brain Health Experts

An expert in behavioral neuroscience with concentrations in Alzheimer's disease and schizophrenia.
A renowned expert on Alzheimer's Disease and other neurodegenerative disorders. 

Recent Brain Health Accomplishments

October 8, 2020
Jefferson Kinney (Brain Health) and James Hyman (Psychology) received a $1.2 million grant from the National Institutes of Aging to continue the research examining the link between Type II diabetes and Alzheimer’s disease. The grant will support them as they continue to investigate the mechanisms underlying Type II diabetes...
June 19, 2020
Dr. Jeffrey Cummings (Brain Health) recently published an article outlining a novel method for determining whether Alzheimer’s drug treatments in clinical trials are ready to move on to the next phase. The paper, “Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach,” was published in The Journal of Dementia...
May 11, 2020
Dr. Jeffrey Cummings (Brain Health) recently published an article, “The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs," in the Journal of Prevention of Alzheimer’s Disease. The somewhat provocative findings note that despite the trend toward prevention trials becoming more likely (in part because trials in...
April 29, 2020
Dr. Jeffery Cummings (Brain Health) and other members of a joint European Union/United States Task Force recently published, “Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease” in the Journal of Prevention of Alzheimer’s Disease. In recognition of the complexity of the disease, the task force acknowledges it may require...
April 10, 2020
Dr. Jeffrey Cummings (Brain Health), recently published an article, “An Actigraphy-Based Validation Study of the Sleep Disorder Inventory (SDI) in the Nursing Home" in Frontiers in Psychiatry. It studied the use of the SDI to identify disrupted sleep in dementia patients in nursing homes, which was proven to be useful when done properly...
April 7, 2020
Dr. Jeffery Cummings (Brain Health) and other members of a joint European Union/United States Task Force recently published, “The Future of Anti-Amyloid Trials,” in the Journal of Prevention and Alzheimer’s Disease. The authors analyze the impact of multiple clinical trials that recently ended for a variety of reasons on the Alzheimer's disease...